Plus Therapeutics (PSTV)
NASDAQ:PSTV
Want to see PSTV full AI Analyst Report?
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$2.90 - $23.44
Previous CloseN/A
Volume69.06K
Average Volume (3M)151.41K
Market Cap
$28.91M
Enterprise Value$8.13M
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$725.00K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 19, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume159,625
30 Day Avg. Volume151,409
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$42.33Price Target Upside7198.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.92
Revenue Forecast (FY)$6.04M
Bulls Say, Bears Say
Bulls Say
Orphan Drug Designation For REYOBIQOrphan designation provides multi-year market exclusivity, fee reductions and tax incentives that materially improve commercial economics and partner interest for a rare CNS indication. This strengthens long-term commercialization prospects and makes partnering or licensing more attractive.
Very High Gross MarginsSustained ~94% gross margins suggest favorable product economics for radiotherapeutics if commercialized, enabling scalable profitability once sales volume ramps. High margins give flexibility on pricing, R&D reinvestment and partner negotiations over the medium term.
Strengthened Development LeadershipAdding an experienced CDO with clinical and development expertise enhances execution capability for complex CNS trials, improving trial design, regulatory interactions and likelihood of timely milestones—raising the odds of durable progress toward approval.
Bears Say
Persistent Negative Cash Flow / Cash BurnSustained large negative operating and free cash flows indicate the company cannot self-fund development at current scale. This structural cash burn forces repeated external financing, which can delay programs and constrain strategic choices absent successful partnering or new revenue.
Very Small, Volatile Revenue And Deep LossesA tiny, inconsistent revenue base plus severe net losses undermines internal funding capacity and obscures sustainable operating leverage. Without predictable revenue growth, margins and profitability remain exposed to financing availability and clinical development setbacks.
Ongoing Reliance On Equity IssuanceFrequent use of on‑demand equity programs signals structural dependence on dilutive financings for working capital. While providing access to capital, this approach regularly dilutes shareholders and reflects an inability to generate positive cash flow from operations in the medium term.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $2.90 and its highest was $23.44 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $28.91M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 58 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.848 by -$0.202.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.848. Following the earnings report the stock price went up 5.31%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
PSTV Stock 12 Month Forecast
Average Price Target
$42.33
▲(7198.85% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---